ASP2905 is a potent and selective potassium channel Kv12.2 inhibitor encoded by the Kcnh3/BEC1 gene. ASP2905 can cross the blood-brain barrier and has antipsychotic activities.
In Vitro
ASP2905 potently inhibits potassium currents in CHO cells expressing KCNH3 (IC 50 of 9.0 nM). ASP2905 (≤10 μM) minimally bound with low affinities to 55 transmembrane proteins. ASP2905 (0.1 µM, 1 µM) decreases the frequency of spontaneous inhibitory postsynaptic currents in cultured rat hippocampal neurons. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
ASP2905 treatment inhibits hyperlocomotion induced by Phencyclidine. And significantly ameliorates Phencyclidine-induced prolongation of immobility time in mice subjected to the forced swimming test. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male ddY mice (aged 4-5 weeks) injected with Phencyclidine hydrochloride (PCP)Dosage: 0.01 mg/kg, 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg Administration: Oral administration; once Result: Inhibited hyperlocomotion induced by Phencyclidine.
Associated Targets
KCNH3Tclin Potassium voltage-gated channel subfamily H member 3 2 Activities
